Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA1c and Age

Clinical Therapeutics
June Felice JohnsonRobert A Bailey

Abstract

Canagliflozin, a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM), has demonstrated effectiveness in patients with T2DM receiving care at a specialty diabetes clinic. We report the outcomes in these patients in subgroups classified by baseline hemoglobin A1c (HbA1c) and age. This subgroup analysis was based on a review of data from the electronic health records of adults with T2DM who were prescribed canagliflozin at a specialty diabetes clinic and who returned for ≥1 follow-up office visit. Mean changes from baseline to the first and second follow-up office visits in HbA1c, body weight, and systolic and diastolic blood pressure (BP) were calculated in each subgroup classified by baseline HbA1c (≥7.0%, ≥8.0%, and >9.0%) and age (<65 and ≥65 years). Of the 462 patients included in the study, 430, 305, and 169 patients had baseline HbA1c ≥7.0%, ≥8.0%, and >9.0%, respectively; 396 and 66 patients were aged <65 and ≥65 years, respectively. With canagliflozin use, patients across subgroups classified by baseline HbA1c and age experienced clinically and statistically significant reductions from baseline in HbA1c, body weight, and systolic BP that were sustained over 2 office vis...Continue Reading

Citations

May 6, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Raffaella GentilellaGiorgio Sesti
Feb 5, 2021·Future Cardiology·Vivencio Barrios, Carlos Escobar
Mar 13, 2021·BMC Medical Research Methodology·Jun Jie Benjamin SengLian Leng Low

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.